Skip to main content

Table 1 Base-case values and ranges used in sensitivity analyses (± 30 %)

From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma

Parameters Base estimate Lower Limit- Upper Limit Assumed distribution
Transition Probability
 PFS for sorafenib 0.1533 0.1073–0.1993 Beta
 PFS To PD for sorafenib 0.0627 0.044–0.082 Beta
 PD To death for sorafenib 0.1184 0.063–0.154 Beta
 PFS for SBRT 0.086 0.061–0.034 Beta
 PFS To PD for SBRT 0.109 0.076–0.142 Beta
 PD To death for SBRT 0.0399 0.028–0.052 Beta
Utility
 PFS for sorafenib 0.76 0.546–1.014 Beta
 PD for sorafenib 0.68 0.476–0.806 Beta
 PFS for SBRT 0.72 0.504–0.936 Beta
 PD for SBRT 0.63 0.441–0.819 Beta
Direct Medical Costs (US$ = 33 NT)    
 cPFS for sorafenib 563365 394355–732375 Constant
 cPFS for SBRT 259056 181339–336773 Constant
 cPD for sorafenib 417528 292270–542786 Constant
 cPD for SBRT 417528 292270–542786 Constant
  1. Abbreviations: c cost, SBRT sterotactic body radiation therapy, PFS progression free survival, PD progression disease